|
 |
|
 |
 |
Name:
Sector:
COO:
|
Gloucester Pharmaceuticals
Healthcare
John McBride
|
|
|
Summary:
|
Develops and commercializes innovative products for the treatment
of cancer. The Company employs an in-licensing strategy to build
a diversified product portfolio. Its first compound, FK228 –
a novel histone deacetylase inhibitor, is in Phase 2 clinical
trials for the treatment of cutaneous T-cell lymphoma as well
as renal cell carcinoma and hormone refractory prostate cancer.
|
|
|
Stage of Initial
Investment:
|
Venture |
Liquidity:
|
Acquired by Celgene
|
|
|
|
|
|
|
|
 |
| |
One Broadway, 14th Floor Cambridge,
MA 02142
Phone: 617.583.1300
Fax: 617.583.1368 |
|
 |
|
|
|
